Atlantic International Corp. (ATLN)
NASDAQIndustrialsMedical - PharmaceuticalsSnapshot 2026-11-04
$0.90-2.16%
Close 2026-07-01 · 1-day change
NASDAQIndustrialsMedical - PharmaceuticalsSnapshot 2026-11-04
Research Workspace
Put ATLN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
The reason to own it still holds.
View ThesisManagement screens weak on capital allocation, earnings delivery.
View ManagementThis stock is volatile — it swings about 5% on a typical day and fell roughly 90% in its worst 12-month stretch.
View RiskATLN is a speculative bet on a turnaround. The company has been unprofitable for a year. Recent financial performance is weak. It sits in the 11th percentile of its sector. Our model puts the next-quarter miss near 74%. Management has been unsteady with frequent change. The market cycle is in a Mania phase. Peer multiples imply a price about 12% above where it trades. This read is provisional. Our standing thesis is intact.
Trailing returns as of 2026-07-01. ATLN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 1 analyst currently covering ATLN (as of Apr 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare ATLN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ATLN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Human Resource & Employment Services — fair value, gap to price, and forward P/E.
Compare the value case
Put ATLN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Achieve $1 billion revenue in 2026
Contract win significantly boosts revenue growth potential.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-01. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.